Axogen agreed to acquire Biocircuit Technologies for $200 million in cash, bringing the FDA-approved Nerve Tape sutureless nerve repair device into Axogen’s peripheral nerve portfolio. The deal is positioned to deepen market control and accelerate uptake. In venture and private markets, Archimed closed its MED IV healthcare fund at €1.5 billion, oversubscribed and more than triple its prior fund size, with plans to deploy capital across biopharma, diagnostics, healthcare IT, med tech, and life science tools. Separately, Frazier Life Sciences secured more than $1.1 billion for a long-running public fund, reinforcing how healthcare-focused investors are continuing to back early- and mid-stage innovation despite valuation and runway pressures.